Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202


Absence of CALR Mutations in Idiopathic Erythrocytosis Patients with Low Serum Erythropoietin Levels.

Catherwood MA, Graham A, Cuthbert RJG, Garrec C, Gardie B, Girodon F, Laird S, Cross NCP, McMullin MF.

Acta Haematol. 2018;139(4):217-219. doi: 10.1159/000489006. Epub 2018 May 30. No abstract available.


A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective.

Greenfield G, McMullin MF.

Expert Rev Hematol. 2018 Jan;11(1):25-35. doi: 10.1080/17474086.2018.1410433. Epub 2017 Dec 2.


The MOSAICC study: Assessing feasibility for biological sample collection in epidemiology studies and comparison of DNA yields from saliva and whole blood samples.

James G, McMullin MF, Duncombe AS, Clarke M, Anderson LA.

Ann Hum Genet. 2018 Mar;82(2):114-118. doi: 10.1111/ahg.12227. Epub 2017 Oct 27.


Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF.

Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9.


70 years of the JCP-highly cited papers: Proposals for the classification of chronic (mature) B and T lymphoid leukaemias.

McMullin MF.

J Clin Pathol. 2017 Nov;70(11):909-910. doi: 10.1136/jclinpath-2017-204759. No abstract available.


Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

Craddock CF, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai SP, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P.

Clin Cancer Res. 2017 Nov 1;23(21):6430-6440. doi: 10.1158/1078-0432.CCR-17-1423. Epub 2017 Aug 1.


Epigenetics in Myeloproliferative Neoplasms.

McPherson S, McMullin MF, Mills K.

J Cell Mol Med. 2017 Sep;21(9):1660-1667. doi: 10.1111/jcmm.13095. Epub 2017 Jul 4. Review.


Equivalence of BCSH and WHO diagnostic criteria for ET.

Harrison CN, McMullin MF, Green AR, Mead AJ.

Leukemia. 2017 Jul;31(7):1660. doi: 10.1038/leu.2017.119. Epub 2017 May 5.


A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.

Leukemia. 2017 May;31(5):1252. doi: 10.1038/leu.2017.2. No abstract available.


HFE mutations in idiopathic erythrocytosis.

Biagetti G, Catherwood M, Robson N, Bertozzi I, Cosi E, McMullin MF, Randi ML.

Br J Haematol. 2018 Apr;181(2):270-272. doi: 10.1111/bjh.14555. Epub 2017 Feb 7. No abstract available.


Experience of Myeloproliferative Neoplasms Guidelines in the United Kingdom: Perspective and International Context.

McMullin MF, Harrison C.

J Natl Compr Canc Netw. 2016 Dec;14(12):e1626-e1631. No abstract available.


Equivalence of BCSH and WHO diagnostic criteria for ET.

Harrison CN, McMullin MF, Green AR, Mead AJ.

Leukemia. 2017 Feb;31(2):527-528. doi: 10.1038/leu.2016.318. Epub 2016 Nov 29. No abstract available. Erratum in: Leukemia. 2017 Jul;31(7):1660.


Primary Familial and Congenital Polycythemia.

Bento C, McMullin MF, Percy M, Cario H.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2016 Nov 10.


Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations.

Camps C, Petousi N, Bento C, Cario H, Copley RR, McMullin MF, van Wijk R, Ratcliffe PJ, Robbins PA, Taylor JC; WGS500 Consortium.

Haematologica. 2016 Nov;101(11):1306-1318. Epub 2016 Sep 20.


A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.

Leukemia. 2017 Apr;31(4):896-902. doi: 10.1038/leu.2016.300. Epub 2016 Oct 24. Erratum in: Leukemia. 2017 May;31(5):1252.


Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

Marchetti M, Barosi G, Cervantes F, Birgegård G, Griesshammer M, Harrison C, Hehlmann R, Kiladjian JJ, Kröger N, McMullin MF, Passamonti F, Vannucchi A, Barbui T.

Leukemia. 2017 Apr;31(4):882-888. doi: 10.1038/leu.2016.283. Epub 2016 Oct 14.


(32)P in the treatment of myeloproliferative disorders.

Lawless S, McMullin MF, Cuthbert R, Houston R.

Ulster Med J. 2016 May;85(2):83-5.


Investigation and Management of Erythrocytosis.

McMullin MF.

Curr Hematol Malig Rep. 2016 Oct;11(5):342-7. doi: 10.1007/s11899-016-0334-1. Review.


The Calreticulin gene and myeloproliferative neoplasms.

Clinton A, McMullin MF.

J Clin Pathol. 2016 Oct;69(10):841-5. doi: 10.1136/jclinpath-2016-203899. Epub 2016 Jun 28. Review.


Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C.

Haematologica. 2016 Aug;101(8):926-31. doi: 10.3324/haematol.2016.146654. Epub 2016 May 12.


Congenital erythrocytosis.

McMullin MF.

Int J Lab Hematol. 2016 May;38 Suppl 1:59-65. doi: 10.1111/ijlh.12506. Epub 2016 May 9. Review.


Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

Liberante FG, Pouryahya T, McMullin MF, Zhang SD, Mills KI.

Oncotarget. 2016 Feb 9;7(6):6609-19. doi: 10.18632/oncotarget.6773.


LNK mutations and myeloproliferative disorders.

McMullin MF, Cario H.

Am J Hematol. 2016 Feb;91(2):248-51. doi: 10.1002/ajh.24259. Review.


The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.

Grinsztejn E, Percy MJ, McClenaghan D, Quintana M, Cuthbert RJ, McMullin MF.

Int J Lab Hematol. 2016 Feb;38(1):102-6. doi: 10.1111/ijlh.12447. Epub 2015 Nov 11.


Management of polycythaemia vera: a critical review of current data.

McMullin MF, Wilkins BS, Harrison CN.

Br J Haematol. 2016 Feb;172(3):337-49. doi: 10.1111/bjh.13812. Epub 2015 Oct 22. Review.


Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group.

Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.


The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jäkel N, Gopalakrishna P, McQuitty M, Stalbovskaya V, Recher C, Theunissen K, Gisslinger H, Kiladjian JJ, Al-Ali HK.

Exp Hematol Oncol. 2015 Sep 15;4:26. doi: 10.1186/s40164-015-0021-2. eCollection 2015.


Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.

Anderson LA, James G, Duncombe AS, Mesa R, Scherber R, Dueck AC, de Vocht F, Clarke M, McMullin MF.

Am J Hematol. 2015 Oct;90(10):864-70. doi: 10.1002/ajh.24098. Epub 2015 Sep 10.


Protein deregulation associated with breast cancer metastasis.

Chan KK, Matchett KB, McEnhill PM, Dakir el H, McMullin MF, El-Tanani Y, Patterson L, Faheem A, Rudland PS, McCarron PA, El-Tanani M.

Cytokine Growth Factor Rev. 2015 Aug;26(4):415-23. doi: 10.1016/j.cytogfr.2015.05.002. Epub 2015 May 31. Review.


Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.

Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, Rimmer A, Kanapin A, Lunter G, Fiddy S, Allan C, Aricescu AR, Attar M, Babbs C, Becq J, Beeson D, Bento C, Bignell P, Blair E, Buckle VJ, Bull K, Cais O, Cario H, Chapel H, Copley RR, Cornall R, Craft J, Dahan K, Davenport EE, Dendrou C, Devuyst O, Fenwick AL, Flint J, Fugger L, Gilbert RD, Goriely A, Green A, Greger IH, Grocock R, Gruszczyk AV, Hastings R, Hatton E, Higgs D, Hill A, Holmes C, Howard M, Hughes L, Humburg P, Johnson D, Karpe F, Kingsbury Z, Kini U, Knight JC, Krohn J, Lamble S, Langman C, Lonie L, Luck J, McCarthy D, McGowan SJ, McMullin MF, Miller KA, Murray L, Németh AH, Nesbit MA, Nutt D, Ormondroyd E, Oturai AB, Pagnamenta A, Patel SY, Percy M, Petousi N, Piazza P, Piret SE, Polanco-Echeverry G, Popitsch N, Powrie F, Pugh C, Quek L, Robbins PA, Robson K, Russo A, Sahgal N, van Schouwenburg PA, Schuh A, Silverman E, Simmons A, Sørensen PS, Sweeney E, Taylor J, Thakker RV, Tomlinson I, Trebes A, Twigg SR, Uhlig HH, Vyas P, Vyse T, Wall SA, Watkins H, Whyte MP, Witty L, Wright B, Yau C, Buck D, Humphray S, Ratcliffe PJ, Bell JI, Wilkie AO, Bentley D, Donnelly P, McVean G.

Nat Genet. 2015 Jul;47(7):717-726. doi: 10.1038/ng.3304. Epub 2015 May 18.


Molecular diagnostics of myeloproliferative neoplasms.

Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, Kjaer L, Lippert E, Mansier O, Oppliger Leibundgut E, Percy MJ, Porret N, Palmqvist L, Schwarz J, McMullin MF, Schnittger S, Pallisgaard N, Hermouet S; MPN&MPNr-EuroNet.

Eur J Haematol. 2015 Oct;95(4):270-9. doi: 10.1111/ejh.12578. Epub 2015 May 18. Review.


A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.

Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE; UK NCRI AML Study Group.

Blood. 2015 Jun 18;125(25):3878-85. doi: 10.1182/blood-2015-01-623447. Epub 2015 Apr 1.


Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.

Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK.

Blood. 2015 May 7;125(19):2923-32. doi: 10.1182/blood-2014-10-608117. Epub 2015 Mar 24.


Outcomes of pregnancy in patients with congenital erythrocytosis.

McMullin MF, Bento C, Rossi C, Rainey MG, Girodon F, Cario H.

Br J Haematol. 2015 Aug;170(4):586-8. doi: 10.1111/bjh.13313. Epub 2015 Mar 2. No abstract available.


Minor allele frequency of myeloproliferative neoplasm mutations in the Irish blood donor population.

Titmarsh GJ, McKay GJ, Lawler M, Anderson LA, McMullin MF.

Hematol Oncol. 2016 Sep;34(3):161-4. doi: 10.1002/hon.2190. Epub 2015 Feb 3.


Management of newly diagnosed chronic myeloid leukaemia during a twin pregnancy using leucapheresis: Case report and review of the literature.

Morris A, McMullin MF, Benson G.

Transfus Apher Sci. 2015 Apr;52(2):199-203. doi: 10.1016/j.transci.2015.01.002. Epub 2015 Jan 8. Review.


Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study.

McMullin MF, James G, Duncombe AS, de Vocht F, Fritschi L, Clarke M, Anderson LA.

Exp Hematol Oncol. 2016 May 26;5:14. doi: 10.1186/s40164-016-0043-4. eCollection 2015.


Update in the myeloproliferative neoplasms.

Harrison CN, McMullin MF.

Clin Med (Lond). 2014 Dec;14 Suppl 6:s66-70. doi: 10.7861/clinmedicine.14-6-s66.


Management of hyperkalaemia.

Bridgham M, Curran S, McMullin MF.

J R Coll Physicians Edinb. 2014;44(1):91-2. No abstract available.


Epidemiology of MPN: what do we know?

Anderson LA, McMullin MF.

Curr Hematol Malig Rep. 2014 Dec;9(4):340-9. doi: 10.1007/s11899-014-0228-z. Review.


Erythrocytosis associated with a novel missense mutation in the BPGM gene.

Petousi N, Copley RR, Lappin TR, Haggan SE, Bento CM, Cario H, Percy MJ; WGS Consortium, Ratcliffe PJ, Robbins PA, McMullin MF.

Haematologica. 2014 Oct;99(10):e201-4. doi: 10.3324/haematol.2014.109306. Epub 2014 Jul 11. No abstract available.


The role of PHD2 mutations in the pathogenesis of erythrocytosis.

Gardie B, Percy MJ, Hoogewijs D, Chowdhury R, Bento C, Arsenault PR, Richard S, Almeida H, Ewing J, Lambert F, McMullin MF, Schofield CJ, Lee FS.

Hypoxia (Auckl). 2014 Jul 1;2:71-90. eCollection 2014. Review.


How common are myeloproliferative neoplasms? A systematic review and meta-analysis.

Titmarsh GJ, Duncombe AS, McMullin MF, O'Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA.

Am J Hematol. 2014 Jun;89(6):581-7. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):850.


Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, Green AR, Mikhaeel G, Gilleece MH, Knapper S, Mead AJ, Mesa RA, Sekhar M, Harrison CN.

Br J Haematol. 2014 Nov;167(3):418-20. doi: 10.1111/bjh.12985. Epub 2014 Jun 25. No abstract available.


Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.

Harrison CN, Butt N, Campbell P, Conneally E, Drummond M, Green AR, Murrin R, Radia DH, Mead A, Reilly JT, Cross NC, McMullin MF.

Br J Haematol. 2014 Nov;167(3):421-3. doi: 10.1111/bjh.12986. Epub 2014 Jun 17. No abstract available.


Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.

Andersen CL, Bjørn ME, McMullin MF, Harrison C, Samuelsson J, Ejerblad E, Zweegman S, Fernandes S, Bareford D, Knapper S, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Skov V, Thomassen M, Kruse T, Grønbæk K, Hasselbalch HC.

Leuk Res. 2014 Jul;38(7):816-21. doi: 10.1016/j.leukres.2014.04.002. Epub 2014 Apr 14.


Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation.

Haslam K, Langabeer SE, Molloy K, McMullin MF, Conneally E.

Br J Haematol. 2014 Sep;166(5):800-2. doi: 10.1111/bjh.12904. Epub 2014 Apr 21. No abstract available.


Secondary erythrocytosis.

McMullin MF.

Hematology. 2014 Apr;19(3):183-4. doi: 10.1179/1024533214Z.000000000263. Epub 2014 Mar 14. No abstract available.


Polycythaemia-inducing mutations in the erythropoietin receptor (EPOR): mechanism and function as elucidated by epidermal growth factor receptor-EPOR chimeras.

Gross M, Ben-Califa N, McMullin MF, Percy MJ, Bento C, Cario H, Minkov M, Neumann D.

Br J Haematol. 2014 May;165(4):519-28. doi: 10.1111/bjh.12782. Epub 2014 Feb 18.


Mutational spectrum defines primary and secondary myelofibrosis.

Mills KI, McMullin MF.

Haematologica. 2014 Jan;99(1):2-3. doi: 10.3324/haematol.2013.101279. No abstract available.

Supplemental Content

Loading ...
Support Center